Avastin

Avastin will continue to be an important first-line option for non-squamous patients who do

not exhibit epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations.

Avelumab

Avelumab (Merck KGaA/Pfizer) is a programmed death-ligand 1 (PD-L1) inhibitor currently under
development for first- and second-line treatment of advanced or metastatic non-small cell lung
cancer (NSCLC).

Azeliragon

Azeliragon is an orally available small molecule that acts as an inhibitor of the receptor for advanced glycation endproducts (RAGE).

Arikayce

Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and

is under development for the treatment of lung infections caused by NTM. These infections can

present in a variety of patients, including those with cystic fibrosis, although Insmed is excluding

these patients from its trials. Insmed has also conducted trials of Arikayce for the specific treatment

of Pseudomonas aeruginosa lung infections in cystic fibrosis patients.

Anacetrapib

The recent discontinuation of anacetrapib’s (Merck & Co) major competitor evacetrapib (Eli Lilly) has
dramatically intensified doubts about the clinical efficacy of the cholesteryl ester transfer protein
(CETP) drug class.